千红制药(002550) - 2020 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2020 was ¥1,667,606,597.33, a decrease of 0.45% compared to ¥1,675,153,096.05 in 2019[22] - The net profit attributable to shareholders of the listed company was -¥132,019,990.55, representing a decline of 150.28% from ¥262,561,171.11 in 2019[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥163,992,891.74, down 16.07% from ¥195,394,677.75 in 2019[22] - The net cash flow from operating activities increased by 96.40% to ¥317,277,947.19 from ¥161,547,891.09 in 2019[22] - The diluted earnings per share for 2020 was ¥-0.11, a decline of 152.38% from ¥0.21 in 2019[25] - The total assets decreased by 16.44% to ¥2,451,779,413.58 at the end of 2020, down from ¥2,934,287,067.26 at the end of 2019[25] - The weighted average return on equity was -6.04% for 2020, a significant drop from 10.70% in 2019[25] - The company reported a net asset attributable to shareholders of ¥2,079,989,811.74, a decrease of 10.80% from ¥2,331,861,745.64 in 2019[25] - The cash dividend payout ratio for 2020 was -113.60%, indicating that the dividends exceeded the net profit attributable to ordinary shareholders[127] - The company reported a net profit of -132,019,990.55 for 2020, which was lower than the cash dividends distributed[127] Revenue Breakdown - The biopharmaceutical segment accounted for 99.95% of total revenue, with revenue of approximately ¥1.67 billion, down 0.40% from the previous year[71] - The raw material drug series generated revenue of approximately ¥709.91 million, representing 42.57% of total revenue, a decrease of 5.45% year-on-year[71] - The formulation drug series saw an increase in revenue to approximately ¥956.79 million, accounting for 57.38% of total revenue, up 3.70% from the previous year[71] - Domestic revenue reached ¥1,058,843,677.04, accounting for 63.49% of total revenue, with a year-on-year increase of 4.33%[74] - International revenue was ¥608,762,920.29, representing 36.51% of total revenue, showing a decline of 7.80% year-on-year[74] Product Development and Market Position - The company has a total of 46 product specifications, primarily focusing on biopharmaceuticals, including active enzymes and polysaccharides[36] - The company plans to expand its product offerings in the biopharmaceutical sector, particularly in the active enzyme series and low molecular weight heparin products[36] - The company achieved a 32% sales increase for standard heparin sodium injection, maintaining the top market share in China[43] - The company has developed a comprehensive heparin product line, with a focus on consistency evaluation for low molecular weight heparin products, becoming a significant growth driver[43] - The market share of Qianhong Heparin Sodium Injection has ranked first in China for four consecutive years, with significant growth in low molecular weight heparin preparations and heparin sodium locking injections[47] Research and Development - The company has filed 191 invention patents in biopharmaceutical innovation, with 97 patents granted, and has obtained three drug production licenses and three Class 1 new drug clinical licenses[48] - Research and development (R&D) investment increased by 12.29% to ¥76,693,280.75 in 2020, compared to ¥68,300,464.57 in 2019[89] - The number of R&D personnel rose by 5.56% to 190 in 2020, while the proportion of R&D personnel decreased from 17.31% to 14.22%[89] - Four new Class I drugs are currently in clinical trials, with one entering international clinical trials, enhancing the company's core competitiveness in innovation[63] Risk Management - The company faces various risks including drug bidding risks, new product development risks, and intensified industry competition[6] - Future development outlook and major risks are detailed in the report, emphasizing the need for investors to be aware of investment risks[6] - The company has established a risk control system to manage various operational risks, including quality, financial, and procurement risks[64] - The board has identified several risks, including the impact of COVID-19 on operations, potential price declines due to drug bidding policies, and increased costs associated with new drug development[119] - The company will implement strict risk control measures to ensure operational stability and compliance with GMP standards, aiming to enhance product quality and core competitiveness[120] Corporate Governance and Compliance - The company is committed to ensuring the accuracy and completeness of its financial reports as stated by its management[5] - The company emphasizes compliance and timely disclosure of important information to protect investors' rights, ranking 35th in the "Listed Companies Sincere Return List"[69] - The company has no significant accounting errors that require retrospective restatement during the reporting period[140] - The company has established a comprehensive quality assurance system to ensure the safety and quality of its pharmaceuticals[180] Social Responsibility and Employee Welfare - The company actively engages in social responsibility initiatives, including support for education, culture, and healthcare[178] - The company has received the "Model Worker Home" title from the All-China Federation of Trade Unions, highlighting its commitment to employee welfare[178] - The company emphasizes employee development through internal and external training programs, fostering a harmonious labor relationship[178] Shareholder Relations and Dividends - The company plans to distribute a cash dividend of ¥1.2 per 10 shares (including tax) based on a total of 1,249,800,000 shares[6] - The company distributed cash dividends of RMB 149,976,000 (including tax) for 2020, amounting to RMB 1.2 per 10 shares, based on a total share base of 1,249,800,000 shares[126] - The retained earnings for 2020 were used for the company's operational activities, with no capital reserve fund conversion to increase share capital[126] - The company has committed to sharing its operational results with shareholders while considering their immediate and long-term interests[131] Environmental Management - The company has implemented an ISO 14001 environmental management system since 2008, focusing on effective waste management and energy efficiency[180] - The company reported a total discharge of COD at 13.38 tons per year and ammonia nitrogen at 0.912 tons per year, adhering to pollution discharge standards[180] - The company has implemented energy-saving technologies in its new facilities to enhance energy efficiency and reduce carbon emissions[180]